Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PLAA | Q9Y263 | 2/20 | 0.39 |
| ▸ | ALPG | P10696 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960305 | 0.80 | ALPL (0.50) | SMN1; SMN2PLAAALPGALDH1A1GAA | |
| SCHEMBL3055990 | 0.77 | AGTR2 (0.43) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3065532 | 0.76 | GRIN1 (0.38) | SMN1; SMN2ALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL13010096 | 0.76 | TLR8 (0.45) | SMN1; SMN2ALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL5766732 | 0.76 | PLAA (0.44) | PLAAALPGALDH1A1KDM4EESR1 | |
| SCHEMBL3582565 | 0.74 | FPR2 (0.43) | SMN1; SMN2PLAAALPGALDH1A1GAA | |
| SCHEMBL4963238 | 0.73 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL3594313 | 0.73 | GFER (0.56) | SMN1; SMN2ALDH1A1GAAKMT2APOLB | |
| SCHEMBL3581846 | 0.72 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL13072246 | 0.72 | SMN1; SMN2 (0.39) | SMN1; SMN2PLAAALPGALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506194-B1 | SUBSTITUTED RING-FUSED IMIDAZOLE DERIVATES: GABA sb A /sb RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2006-07-19 | — | — | EP | disclosed |
| US-6916827-B2 | Substituted ring-fused imidazole derivative: GABAA receptors ligands | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1506194-A1 | SUBSTITUTED RING-FUSED IMIDAZOLE DERIVATES: GABA sb A /sb RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040014780-A1 | Substituted ring-fused imidazole derivative: GABAA receptors ligands | NEUROGEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| WO-2003097643-A1 | SUBSTITUTED RING-FUSED IMIDAZOLE DERIVATES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014780-A1 | Substituted ring-fused imidazole derivative: GABAA receptors ligands | GABRB1, GABRA1, GABRB3 | SMN1; SMN2 850/4885PLAA 4545/4885ALPG 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.